An open-label Phase 2a study of fasudil in amyotrophic lateral sclerosis: safety and exploratory endpoints
{{output}}
Objectives: The primary objective was to assess the safety of oral fasudil in amyotrophic lateral sclerosis (ALS) patients. Changes in serum neurofilament light (NfL) levels and the ratio of phosphorylated to total AKT (pAKT/tAKT... ...
